• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nasdaq Dips 300 Points; Johnson & Johnson Earnings Top Estimates

    7/17/24 9:39:19 AM ET
    $ADTX
    $ASLN
    $JNJ
    $LCFY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADTX alert in real time by email

    U.S. stocks traded mostly lower this morning, with the Nasdaq Composite falling around 300 points on Wednesday.

    Following the market opening Wednesday, the Dow traded down 0.10% to 40,914.80 while the NASDAQ fell 1.63% to 18,208.05. The S&P 500 also fell, dropping, 0.98% to 5,611.77                                 .

    Check This Out: Amazon To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Wednesday

    Leading and Lagging Sectors

    Energy shares jumped by 0.5% on Wednesday.

    In trading on Wednesday, information technology shares fell by 2.3%.

    Top Headline

    Johnson & Johnson (NYSE:JNJ) reported better-than-expected second-quarter earnings on Wednesday.

    The company posted adjusted EPS of $2.82, up 10.2% year-over-year, beating the consensus of $2.70. The pharma giant reported sales of $22.45 billion, up 4.3% year-over-year, beating the consensus of $22.31 billion.

    Johnson & Johnson raised fiscal year 2024 operational sales guidance to $89.2 billion-$89.6 billion versus prior guidance of $88.7 billion-$89.1 billion.

    Equities Trading UP
                           

    • Aditxt, Inc. (NASDAQ:ADTX) shares shot up 67% to $2.66. Aditxt and Evofem amended merger agreement.
    • Shares of Locafy Limited (NASDAQ:LCFY) got a boost, surging 41% to $7.69.
    • Shimmick Corporation (NASDAQ:SHIM) shares were also up, gaining 36% to $2.74 after the company received a $27.6 million subcontract for the Sunol Valley Water Treatment Plant Ozonation Project.

    Equities Trading DOWN

    • ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) shares dropped 57% to $0.4813 after the company announced that its Singapore-incorporated, sole operating subsidiary has filed for voluntary liquidation.
    • Shares of Cassava Sciences, Inc. (NASDAQ:SAVA) were down 27% to $9.91 after announcing changes in executive leadership. The company named Rick Barry as Executive Chairman and Principal Executive Office and said Remi Barbier resigned as President, CEO, and Board Member.
    • NaaS Technology Inc. (NASDAQ:NAAS) was down, falling 14% to $4.0097.

    Also Check This Out: Alphabet, CrowdStrike And 2 Other Stocks Insiders Are Selling

    Commodities

    In commodity news, oil traded up 0.6% to $81.23 while gold traded up 0.2% at $2,473.50.

    Silver traded down 1% to $31.155 on Wednesday, while copper fell 0.5% to $4.4285.

    Euro zone

    European shares were lower today. The eurozone's STOXX 600 fell 0.6%, Germany's DAX fell 0.6% and France's CAC 40 fell 0.5%. Spain's IBEX 35 Index fell 0.2%, while London's FTSE 100 fell 0.1%.

    Annual inflation rate in the Eurozone eased to 2.5% in June from 2.6% in May. French current account deficit shrank to EUR 3.1 billion in May versus a revised EUR 3.5 billion in the prior month.

    U.K. producer prices increased 1.4% year-over-year in June following a 1.7% rise in the prior month, while annual inflation rate came in steady at 2% in June.

    Asia Pacific Markets

    Asian markets closed mixed on Wednesday, with Japan's Nikkei 225 falling 0.43%, Hong Kong's Hang Seng Index gaining 0.06% and China's Shanghai Composite Index falling 0.45%.

    Singapore’s non-oil domestic exports fell by 8.7% year-over-year in June following a revised 0.7% decline in May.

    Economics

    • U.S. mortgage applications climbed by 3.9% during the third week of July.
    • U.S. housing starts increased by 3% from the prior month to an annualized rate of 1,314,000 in June compared to a revised 4.6% fall a month ago.
    • Building permits in the U.S. climbed by 3.4% to an annual rate of 1.446 million in June.

    Now Read This: How To Earn $500 A Month From Domino’s Stock Ahead Of Q2 Earnings Report

    Get the next $ADTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADTX
    $ASLN
    $JNJ
    $LCFY

    CompanyDatePrice TargetRatingAnalyst
    Johnson & Johnson
    $JNJ
    4/8/2026$250.00Buy
    TD Cowen
    Shimmick Corporation
    $SHIM
    3/13/2026$5.00Neutral → Buy
    Roth Capital
    Johnson & Johnson
    $JNJ
    1/28/2026$262.00Equal-Weight → Overweight
    Morgan Stanley
    Shimmick Corporation
    $SHIM
    1/5/2026$6.00Hold → Buy
    Craig Hallum
    Johnson & Johnson
    $JNJ
    11/13/2025$230.00Sector Outperform
    Scotiabank
    Johnson & Johnson
    $JNJ
    10/20/2025$203.00Neutral → Outperform
    Daiwa Securities
    Johnson & Johnson
    $JNJ
    10/3/2025$212.00Equal Weight → Overweight
    Wells Fargo
    Johnson & Johnson
    $JNJ
    9/23/2025$206.00Neutral → Buy
    Guggenheim
    More analyst ratings

    $ADTX
    $ASLN
    $JNJ
    $LCFY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $24,061 worth of Class A Shares (72,912 units at $0.33) and sold $3,595 worth of Class A Shares (11,982 units at $0.30), increasing direct ownership by 100% to 121,592 units (SEC Form 4)

    4 - Aditxt, Inc. (0001726711) (Issuer)

    4/23/26 3:43:04 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Hrt Financial Lp claimed ownership of 133,574 units of Class A Shares (SEC Form 3)

    3 - Aditxt, Inc. (0001726711) (Issuer)

    4/23/26 3:37:12 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Yoder Todd Wilbur

    4 - Shimmick Corp (0001887944) (Issuer)

    4/16/26 4:16:39 PM ET
    $SHIM
    Military/Government/Technical
    Industrials

    $ADTX
    $ASLN
    $JNJ
    $LCFY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $24,061 worth of Class A Shares (72,912 units at $0.33) and sold $3,595 worth of Class A Shares (11,982 units at $0.30), increasing direct ownership by 100% to 121,592 units (SEC Form 4)

    4 - Aditxt, Inc. (0001726711) (Issuer)

    4/23/26 3:43:04 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Chief Financial Officer Yoder Todd Wilbur bought $5,600 worth of shares (2,000 units at $2.80) (SEC Form 4)

    4/A - Shimmick Corp (0001887944) (Issuer)

    12/2/25 4:18:47 PM ET
    $SHIM
    Military/Government/Technical
    Industrials

    Director Anderson Robert Eugene Jr bought $24,940 worth of shares (8,600 units at $2.90) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/25/25 4:06:25 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $ASLN
    $JNJ
    $LCFY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen resumed coverage on Johnson & Johnson with a new price target

    TD Cowen resumed coverage of Johnson & Johnson with a rating of Buy and set a new price target of $250.00

    4/8/26 8:36:42 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shimmick Corp. upgraded by Roth Capital with a new price target

    Roth Capital upgraded Shimmick Corp. from Neutral to Buy and set a new price target of $5.00

    3/13/26 9:09:34 AM ET
    $SHIM
    Military/Government/Technical
    Industrials

    Johnson & Johnson upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Johnson & Johnson from Equal-Weight to Overweight and set a new price target of $262.00

    1/28/26 7:11:28 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $ASLN
    $JNJ
    $LCFY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

    Through 120 weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+Patients achieving sustained minimal symptom expression (MSE) experienced greater improvements in quality of life than those with transient MSE in a post-hoc analysis of the Phase 3 studyEPIC, the first head-to-head study of IMAAVY versus another FcRn blocker in generalized myasthenia gravis, is now enrolling participantsHORSHAM, Pa., April 22, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new data from the Phase 3 Vivacity-MG3 study and ongoing open label extension (OLE) in a broad population o

    4/22/26 8:05:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

    Johnson & Johnson (NYSE:JNJ) will participate in the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19th. Management will participate in a Fireside Chat at 11:30 a.m. Eastern Time. This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com. The audio webcast replay will be available approximately 48 hours after the webcast. View source version on businesswire.com: https://www.businesswire.com/news/home/20260421719308/en/ Media contact: [email protected] Investor contact: [email protected]

    4/21/26 4:22:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026

    As Johnson & Johnson celebrates 30 years of CARTO, the launch of CARTOSOUND SONATA brings new AI-based imaging and mapping capabilitiesi to electrophysiology A total of 17 abstracts will be presented, including new clinical data for the VARIPULSE Platform Johnson & Johnson today announced it will showcase the latest advances across its electrophysiology portfolio at the 2026 Heart Rhythm Society (HRS) Annual Meeting, including new evidence in pulsed field ablation (PFA), and innovations in cardiac mapping and imaging. At HRS 2026, the company will launch the CARTOSOUND SONATA Module, leveraging artificial intelligence with the CARTO System to automatically transform intracardiac echoc

    4/21/26 7:45:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $ASLN
    $JNJ
    $LCFY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

    For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

    5/5/22 4:51:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

    For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

    8/18/21 1:06:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $ASLN
    $JNJ
    $LCFY
    SEC Filings

    View All

    Amendment: SEC Form F-1/A filed by NaaS Technology Inc.

    F-1/A - NaaS Technology Inc. (0001712178) (Filer)

    4/24/26 11:44:26 AM ET
    $NAAS
    Other Specialty Stores
    Consumer Discretionary

    SEC Form 424B3 filed by Aditxt Inc.

    424B3 - Aditxt, Inc. (0001726711) (Filer)

    4/23/26 4:30:42 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Shimmick Corporation

    DEF 14A - Shimmick Corp (0001887944) (Filer)

    4/22/26 4:09:56 PM ET
    $SHIM
    Military/Government/Technical
    Industrials

    $ADTX
    $ASLN
    $JNJ
    $LCFY
    Financials

    Live finance-specific insights

    View All

    Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%

    Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a 3.1% increase in the quarterly dividend, from $1.30 per share to $1.34 per share, marking the 64th year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $5.36 per share compared to the previous rate of $5.20 per share. The next quarterly dividend is payable on June 9, 2026 to shareholders of record at the close of business on May 26, 2026. The ex-dividend date is May 26, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, tr

    4/14/26 6:21:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson reports Q1 2026 results, raises 2026 outlook

    2026 First-Quarter reported sales growth of 9.9% to $24.1 Billion with operational growth of 6.4%* and adjusted operational growth of 5.3%* 2026 First-Quarter earnings per share (EPS) of $2.14 and adjusted EPS of $2.70 Company increases 2026 guidance with estimated reported sales of $100.8 Billion or 7.0% at the midpoint, and adjusted EPS4 of $11.55 or 7.1% at the midpoint Solidifying path to double-digit growth by the end of the decade, with significant progress for patients with the approvals of ICOTYDE the first-and-only targeted oral peptide for plaque psoriasis, TECVAYLI plus DARZALEX FASPRO as early as second line for patients with relapsed/refractory multiple myeloma, VARIP

    4/14/26 6:20:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

    Ignite plans to launch a new program in 2026 supporting treatment selection for more than 600,000 people in the United States living with metastatic cancer and limited therapeutic options. Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the acquisition of Ignite Proteomics, LLC ("Ignite"), a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite's functional proteomics platform has demonstrated the ability to identify cancer therapy responses that may not be captured by standard genomic testing alone. Aditxt

    3/13/26 8:15:00 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $ASLN
    $JNJ
    $LCFY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NaaS Technology Inc.

    SC 13G/A - NaaS Technology Inc. (0001712178) (Subject)

    11/14/24 9:58:25 PM ET
    $NAAS
    Other Specialty Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by NaaS Technology Inc.

    SC 13G/A - NaaS Technology Inc. (0001712178) (Subject)

    11/14/24 5:31:20 PM ET
    $NAAS
    Other Specialty Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Cassava Sciences Inc.

    SC 13G/A - CASSAVA SCIENCES INC (0001069530) (Subject)

    11/4/24 4:09:49 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $ASLN
    $JNJ
    $LCFY
    Leadership Updates

    Live Leadership Updates

    View All

    Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

    Busch brings public company leadership and capital markets experience to support Ignite's next phase of growth Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein profiling. The platform measures active proteins inside tumors to help oncologists determine which targeted therapies are most

    3/19/26 8:15:00 AM ET
    $ADTX
    $GMRE
    $XRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    Cassava Reports Q3 2025 Financials Results and Provides Business Update

    Simufilam advancing towards a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyFurther fortified our strategic capabilities with the appointment of Dawn C. Bir to the Board of Directors$106.1 million in cash and cash equivalents at September 30, 2025. Expected to support operations into 2027 AUSTIN, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- – Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the third quarter ende

    11/12/25 8:00:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

    AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Ms. Dawn C. Bir to its Board of Directors (the Board). Dawn Bir is a seasoned biopharmaceutical executive and board member with a track record of contributing to the successful development and value creation for pre-commercial and commercial biotechnology and life science companies including Reata Pharmaceuticals, Inc. (acquired by Biogen Inc.), Geron Corporation,

    10/22/25 8:00:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care